Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms

Figures & data

Table 1 Clinicopathological Characteristics of All Patients

Variables	n	FAR<0.08	FAR≥ 0.08	P
Total	324	228	96
Age (years), n (%)				0.001
< 60	225	171 (75.0)	54 (56.3)
≥ 60	99	57 (25.0)	42 (43.7)
Sex, n (%)				0.146
Female	182	134 (58.8)	48 (50.0)
Male	142	94 (41.2)	48 (50.0)
Location, n (%)				0.934
Head	126	89 (39.0)	37 (38.5)
Body or tail	198	137 (61.0)	59 (61.5)
Functioning tumors, n (%)				<0.001
Yes	34	33 (13.9)	1 (1.6)
No	290	195 (86.1)	95 (98.4)
Tumor grade, n (%)^a				0.032
Grade 1	124	94 (42.5)	30 (31.3)
Grade 2	154	106 (48.0)	48 (50.0)
Grade 3	39	21 (9.5)	18 (18.8)
Tumor stage, n (%)				0.001
I	77	62 (27.2)	15 (15.6)
II	117	86 (37.7)	31 (32.3)
III	40	31 (13.6)	9 (9.4)
Ⅳ	90	49 (21.5)	41 (42.7)
Tumor differentiation, n (%)				0.046
Well	293	211 (92.5)	82 (85.4)
Poor	31	17 (7.5)	14 (14.6)
Radical surgery, n (%)				<0.001
Yes	238	181 (79.4)	57 (59.4)
No	86	47 (20.6)	39 (40.6)
Body mass index, n (%)^b				0.946
<18.5	21	15 (6.9%)	6 (6.7%)
≥18.5	287	203 (93.1%)	84 (93.3%)

Notes: ^aData of tumor grade for 7 patients with were missing; ^bdata of body mass index for 16 patients were missing.

Abbreviation: FAR, fibrinogen/albumin ratio.

Table 2 Univariate and Multivariate Analyses for the Overall Survival of All Patients According to Their Baseline FAR

Variables	Univariate Analysis			Multivariate Analysis
	HR	95% CI	P	HR	95% CI	P
Age (years)
< 60	1			1
≥ 60	0.99	0.53–1.85	0.973	0.861	0.431–1.72	0.671
Sex
Female	1			1
Male	0.64	0.36–1.13	0.125	1.716	0.855–3.446	0.129
Location
Head	1			1
Body or tail	0.82	0.46–1.47	0.506	0.347	0.173–0.694	0.003
Functioning tumors
Yes	1			1
No	0.15	0.02–1.08	0.059	0.836	0.101–6.924	0.868
Tumor grade
Grade 1	1			1
Grade 2	3.92	1.48–10.36	0.006	5.498	1.197–25.245	0.028
Grade 3	20.04	7.49–53.63	<0.001	16.377	3.313–80.953	0.001
Tumor stage
I	1			1
II	2.80	0.33–24.02	0.347	1.120	0.109–11.45	0.924
III	16.91	2.08–137.72	0.008	3.612	0.376–34.682	0.266
Ⅳ	45.47	6.21–333.12	<0.001	7.792	0.759–80.04	0.084
Radical surgery
Yes	1			1
No	8.14	4.43–14.97	<0.001	2.813	0.921–8.586	0.069
Body mass index
<18.5
≥18.5	0.443	0.173–1.131	0.089	1.504	0.559–4.047	0.419
FAR
<0.08	1			1
≥0.08	3.87	2.17–6.90	<0.001	4.56	2.306–9.567	<0.001

Abbreviations: HR, hazard ratio; FAR, fibrinogen/albumin ratio.

Figure 1 Kaplan–Meier plot of OS for all patients stratified into two groups: patients with a FAR ≥0.08 and patients with a FAR < 0.08.

Figure 2 Kaplan–Meier plot of PFS for all patients stratified into two groups: patients with a FAR ≥0.08 and patients with a FAR < 0.08.

Table 3 Univariate and Multivariate Analyses for the Progression-Free Survival of All Patients According to Their Baseline FAR

Variables	Univariate Analysis			Multivariate Analysis
	HR	95% CI	P	HR	95% CI	P
Age (years)
< 60	1			1
≥ 60	1.02	0.69–1.52	0.916	0.677	0.436–1.052	0.083
Sex
Female	1			1
Male	0.69	0.48–1.00	0.050	0.743	0.493–1.121	0.157
Location
Head	1			1
Body or tail	1.48	01.00–2.19	0.048	1.090	0.705–1.685	0.700
Functioning tumors
Yes	1			1
No	0.38	0.17–0.86	0.021	0.876	0.537–2.148	0.772
Tumor grade
Grade 1	1			1
Grade 2	3.61	2.12–6.15	<0.001	1.491	0.789–2.818	0.219
Grade 3	10.66	5.87–19.37	<0.001	1.920	0.919–4.011	0.083
Tumor stage
I	1			1
II	6.06	1.43–25.62	0.014	4.969	1.138–21.704	0.033
III	15.99	3.68–69.59	<0.001	7.579	1.613–35.613	0.010
Ⅳ	71.57	17.45–293.53	<0.001	27.168	5.524–133.621	<0.001
Radical surgery
Yes	1			1
No	8.93	6.02–13.24	<0.001	1.827	0.88–6.07	0.072
Body mass index
<18.5
≥18.5	0.434	0.225–0.837	0.013	0.796	0.399–1.586	0.516
FAR
<0.08	1			1
≥0.08	2.37	1.64–3.42	<0.001	1.803	1.185–2.744	0.006

Abbreviations: HR, hazard ratio; FAR, fibrinogen/albumin ratio.

Figure 3 Kaplan–Meier plot of OS for patients without radical surgical resection stratified into two groups: patients with a FAR ≥0.08 and patients with a FAR < 0.08.

Figure 4 Kaplan–Meier plot of PFS for patients without radical surgical resection stratified into two groups: patients with a FAR ≥0.08 and patients with a FAR < 0.08.